Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer Grant Program

The Pfizer Independent Medical Education competitive grant program titled Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer is a targeted funding opportunity designed to support educational initiatives that improve healthcare professional knowledge and clinical practice in oncology. Pfizer, a global biopharmaceutical company, administers this program through an internal review process as part of its broader commitment to advancing healthcare education and improving patient outcomes. The grant specifically focuses on addressing knowledge gaps related to ALK-positive metastatic non-small cell lung cancer, particularly in community oncology settings where access to the latest clinical data and treatment strategies may be limited. The primary purpose of this grant is to fund independent medical education activities that enhance understanding of the most recent clinical data and promote effective therapy management strategies for patients receiving ALK tyrosine kinase inhibitor based treatments. Projects are expected to emphasize practical approaches to managing adverse events such as weight gain, hyperlipidemia, and central nervous system effects, as well as improving diagnostic and treatment workflows. The scope of supported activities includes a wide range of educational formats such as peer-to-peer learning platforms, digital content, live conference sessions, and training curricula updates, all aimed at improving real-world clinical practice and patient care outcomes. Funding is available for individual projects requesting up to 250000 dollars, with Pfizer indicating an intent to support approximately two to three proposals. The maximum project duration is one year from the anticipated start date, which is expected to begin in September 2026 or later. Funding may be used for direct project costs as well as institutional overhead, which is capped at 28 percent of the total budget. However, funds may not be used to support clinical research evaluating therapeutic or diagnostic efficacy, nor may they be used to purchase therapeutic assets. The program does not require cost sharing or matching funds, and applicants are responsible for the independent design and execution of their educational initiatives. Eligibility for this grant is limited to organizations based in the United States that have a mission aligned with healthcare professional education or healthcare improvement. Eligible applicants include medical and nursing schools, healthcare institutions, professional societies, medical education companies, and similar entities. Individuals and unaffiliated physician practice groups are not eligible. Organizations must be legally able to receive funding directly from Pfizer and, if offering continuing education credit, must hold appropriate accreditation. Additional requirements include disclosure of any use of artificial intelligence in preparing the application and ensuring that the project lead is affiliated with the applicant organization. The application process requires submission through the Pfizer CyberGrants portal, where applicants must complete all required fields and upload a detailed project proposal. The proposal must include sections such as goals and objectives, needs assessment, target audience, project design, innovation, evaluation methods, dissemination plan, timeline, organizational roles, and budget details. Applicants must also correctly select the competitive grant designation and specify the appropriate program name and area of interest within the portal. Pfizer conducts an internal review of all submitted proposals and may request additional information during the evaluation process. Key dates for this funding opportunity include a release date of May 20, 2026, and a submission deadline of July 15, 2026 at 23:59 Eastern Time. Applications submitted after the deadline will not be considered. Grant award notifications are anticipated by August 3, 2026, with projects expected to commence in September 2026 or later. All applicants will be notified of funding decisions via email. Successful applicants must enter into a formal grant agreement with Pfizer, and funding will be disbursed to the organization rather than individuals. This grant is part of Pfizer’s broader independent medical education initiative, which supports programs designed to address unmet medical needs and improve patient outcomes through education. While Pfizer provides funding, it maintains no involvement in the development or execution of the educational content, ensuring the independence and integrity of the supported programs. The opportunity is not described as recurring, and therefore appears to be a one-time competitive funding cycle aligned with current clinical priorities in oncology.

Focus on addressing community oncology gaps and demonstrating measurable impact on clinical practice; emphasize practical management strategies and real world applicability; align clearly with stated educational priorities